Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: Major effect on CYPs 2B6, 2C9, 2C19, and 3A

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 2, 2009, Pages 541-551

  Jeong, Seongwook ^a,c   Nguyen, Phuong D ^a   Desta, Zeruesenay ^a,b  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Chonnam National University Medical School   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; VORICONAZOLE;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; ENZYME INACTIVATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; LOADING DRUG DOSE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIFUNGAL AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DATA INTERPRETATION, STATISTICAL; ENZYME INHIBITORS; HUMANS; ISOENZYMES; KINETICS; MICROSOMES, LIVER; PILOT PROJECTS; PYRIMIDINES; SPECTROPHOTOMETRY, ULTRAVIOLET; TRIAZOLES;

EID: 59749096795     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01123-08     Document Type: Article

References (70)

1. Abelo, A., T. B. Andersson, M. Antonsson, A. K. Naudot, I. Skanberg, and L. Weidolf. 2000. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab. Dispos. 28:966-972.
2. Andersson, T. 1996. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin. Pharmacokinet. 31:9-28.
3. Bertz, R. J., and G. R. Granneman. 1997. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. 32:210-258.
4. Bourrie, M., V. Meunier, Y. Berger, and G. Fabre. 1996. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmacol. Exp. Ther. 277:321-332.
5. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254.
6. Broly, F., C. Libersa, M. Lhermitte, P. Bechtel, and B. Dupuis. 1989. Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver. Br. J. Clin. Pharmacol. 28:29-36.
7. Bumpus, N. N., C. Sridar, U. M. Kent, and P. F. Hollenberg. 2005. The naturally occurring cytochrome P450 (P450) 2B6 K262R mutant of P450 2B6 exhibits alterations in substrate metabolism and inactivation. Drug Metab. Dispos. 33:795-802.
8. Desta, Z., T. Kerbusch, N. Soukhova, E. Richard, J. W. Ko, and D. A. Flockhart. 1998. Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. J. Pharmacol. Exp. Ther. 285:428-437.
9. Desta, Z., T. Saussele, B. Ward, J. Blievernicht, L. Li, K. Klein, D. A. Flockhart, and U. M. Zanger. 2007. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 8:547-558.
10. Desta, Z., N. V. Soukhova, and D. A. Flockhart. 2001. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob. Agents Chemother. 45:382-392.
11. Desta, Z., X. Zhao, J. G. Shin, and D. A. Flockhart. 2002. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 41:913-958.
12. Dowell, J. A., J. Schranz, A. Baruch, and G. Foster. 2005. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. J. Clin. Pharmacol. 45:1373-1382.
13. Draper, A. J., A. Madan, and A. Parkinson. 1997. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. Arch. Biochem. Biophys. 341:47-61.
14. Eap, C. B., T. Buclin, and P. Baumann. 2002. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin. Pharmacokinet. 41:1153-1193.
15. Faucette, S. R., R. L. Hawke, E. L. Lecluyse, S. S. Shord, B. Yan, R. M. Laethem, and C. M. Lindley. 2000. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab. Dispos. 28:1222-1230.
16. FDA Antiviral Drugs Advisory Committee. 2001. Briefing document for Voriconazole. 4 October 2001. FDA, Rockville, MD.
17. FDA (Clinical Pharmacology). 2006 Guidance for industry: drug interaction studies - study design, data analysis, and implications for dosing and labeling. FDA, Rockville, MD.
18. Gorski, J. C., S. D. Hall, D. R. Jones, M. Vandenbranden, and S. A. Wrighton. 1994. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem. Pharmacol. 47:1643-1653.
19. Gorski, J. C., S. Vannaprasaht, M. A. Hamman, W. T. Ambrosius, M. A. Bruce, B. Haehner-Daniels, and S. D. Hall. 2003. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin. Pharmacol. Ther. 74:275-287.
20. Greenlee, W. F., and A. Poland. 1978. An improved assay of 7-ethoxycoumarin O-deethylase activity: induction of hepatic enzyme activity in C57BL/6J and DBA/2J mice by phenobarbital, 3-methylcholanthrene and 2,3,7,8-tetrachlorodibenzo-p-dioxin. J. Pharmacol. Exp. Ther. 205:596-605.
21. Haas, D. W., H. J. Ribaudo, R. B. Kim, C. Tierney, G. R. Wilkinson, R. M. Gulick, D. B. Clifford, T. Hulgan, C. Marzolini, and E. P. Acosta. 2004. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 18:2391-2400.
22. Hagelberg, N. M., T. H. Nieminen, T. I. Saari, M. Neuvonen, P. J. Neuvonen, K. Laine, and K. T. Olkkola. 3 October 2008. Voriconazole drastically increases exposure to oral oxycodone. Eur. J. Clin. Pharmacol. [Epub ahead of print.]
23. Hulot, J. S., A. Bura, E. Villard, M. Azizi, V. Remones, C. Goyenvalle, M. Aiach, P. Lechat, and P. Gaussem. 2006. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108:2244-2247.
24. Hyland, R., B. C. Jones, and D. A. Smith. 2003. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab. Dispos. 31:540-547.
25. Hynninen, V. V., K. T. Olkkola, L. Bertilsson, K. Kurkinen, P. J. Neuvonen, and K. Laine. 2008. Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine. Clin. Pharmacol. Ther. 83:342-348.
26. Hynninen, V. V., K. T. Olkkola, K. Leino, S. Lundgren, P. J. Neuvonen, A. Rane, M. Valtonen, and K. Laine. 2007. Effect of voriconazole on the pharmacokinetics of diclofenac. Fundam. Clin. Pharmacol. 21:651-656.
27. Hynninen, V. V., K. T. Olkkola, K. Leino, S. Lundgren, P. J. Neuvonen, A. Rane, M. Valtonen, H. Vyyrylainen, and K. Laine. 2006. Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of S-(+)-and R-(-)-ibuprofen. Antimicrob. Agents Chemother. 50:1967-1972.
28. Hynninen, V. V., K. T. Olkkola, P. J. Neuvonen, and K. Laine. 9 September 2008. Oral voriconazole and miconazole oral gel produce comparable effects on the pharmacokinetics and pharmacodynamics of etoricoxib. Eur. J. Clin. Pharmacol. [Epub ahead of print.]
29. Kenworthy, K. E., J. C. Bloomer, S. E. Clarke, and J. B. Houston. 1999. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br. J. Clin. Pharmacol. 48:716-727.
30. Kirchheiner, J., and J. Brockmoller. 2005. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther. 77:1-16.
31. Ko, J. W., Z. Desta, N. V. Soukhova, T. Tracy, and D. A. Flockhart. 2000. In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6. Br. J. Clin. Pharmacol. 49:343-351.
32. Ko, J. W., N. Sukhova, D. Thacker, P. Chen, and D. A. Flockhart. 1997. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab. Dispos. 25:853-862.
33. Kronbach, T., D. Mathys, M. Umeno, F. J. Gonzalez, and U. A. Meyer. 1989. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol. Pharmacol. 36:89-96.
34. Li, X. Q., A. Bjorkman, T. B. Andersson, M. Ridderstrom, and C. M. Masimirembwa. 2002. Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J. Pharmacol. Exp. Ther. 300:399-407.
35. Li, Y., J. Hou, H. Jiang, D. Wang, W. Fu, Z. Yuan, Y. Chen, and L. Zhou. 2007. Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide based regimens in multiple myeloma. Haematologica 92:1246-1249.
36. Liu, P., G. Foster, R. Labadie, E. Somoza, and A. Sharma. 2007. Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy. Antimicrob. Agents Chemother. 51:110-118.
37. Liu, P., G. Foster, R. R. LaBadie, M. J. Gutierrez, and A. Sharma. 2008. Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects. J. Clin. Pharmacol. 48:73-84.
38. Mouly, S., K. S. Lown, D. Kornhauser, J. L. Joseph, W. D. Fiske, I. H. Benedek, and P. B. Watkins. 2002. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin. Pharmacol. Ther. 72:1-9.
39. Muijsers, R. B., K. L. Goa, and L. J. Scott. 2002. Voriconazole: in the treatment of invasive aspergillosis. Drugs 62:2655-2664.
40. Murayama, N., N. Imai, T. Nakane, M. Shimizu, and H. Yamazaki. 2007. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochem. Pharmacol. 73:2020-2026.
41. Niwa, T., S. Inoue-Yamamoto, T. Shiraga, and A. Takagi. 2005. Effect of antifungal drugs on cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 activities in human liver microsomes. Biol. Pharm. Bull. 28:1813-1816.
42. Niwa, T., T. Shiraga, and A. Takagi. 2005. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol. Pharm. Bull. 28:1805-1808.
43. Niwa, T., T. Shiraga, and A. Takagi. 2005. Drug-drug interaction of antifungal drugs. Yakugaku Zasshi 125:795-805. (In Japanese.)
44. Parikh, S., J. B. Ouedraogo, J. A. Goldstein, P. J. Rosenthal, and D. L. Kroetz. 2007. Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin. Pharmacol. Ther. 82:197-203.
45. Pearce, R., D. Greenway, and A. Parkinson. 1992. Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: effects on coumarin, dicumarol, and testosterone oxidation. Arch. Biochem. Biophys. 298:211-225.
46. Pearson, M. M., P. D. Rogers, J. D. Cleary, and S. W. Chapman. 2003. Voriconazole: a new triazole antifungal agent. Ann. Pharmacother. 37:420-432.
47. Pfizer Inc. 2008. Voriconazole prescribing information, March 2008 revision. Pfizer Inc., New York, NY.
48. Purkins, L., N. Wood, P. Ghahramani, E. R. Love, M. D. Eve, and A. Fielding. 2003. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br. J. Clin. Pharmacol. 56(Suppl. 1):37-44.
49. Purkins, L., N. Wood, D. Kleinermans, and D. Nichols. 2003. Voriconazole potentiates warfarin-induced prothrombin time prolongation. Br. J. Clin. Pharmacol. 56(Suppl. 1):24-29.
50. Relling, M. V., T. Aoyama, F. J. Gonzalez, and U. A. Meyer. 1990. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J. Pharmacol. Exp. Ther. 252:442-447.
51. Roffey, S. J., S. Cole, P. Comby, D. Gibson, S. G. Jezequel, A. N. Nedderman, D. A. Smith, D. K. Walker, and N. Wood. 2003. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab. Dispos. 31:731-741.
52. Saari, T. I., K. Laine, L. Bertilsson, P. J. Neuvonen, and K. T. Olkkola. 2007. Voriconazole and fluconazole increase the exposure to oral diazepam. Eur. J. Clin. Pharmacol. 63:941-949.
53. Saari, T. I., K. Laine, K. Leino, M. Valtonen, P. J. Neuvonen, and K. T. Olkkola. 2006. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin. Pharmacol. Ther. 79: 362-370.
54. Saari, T. I., K. Laine, K. Leino, M. Valtonen, P. J. Neuvonen, and K. T. Olkkola. 2006. Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. Clin. Pharmacol. Ther. 80:502-508.
55. Saari, T. I., K. Laine, M. Neuvonen, P. J. Neuvonen, and K. T. Olkkola. 2008. Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl. Eur. J. Clin. Pharmacol. 64:25-30.
56. Scott, L. J., and D. Simpson. 2007. Voriconazole: a review of its use in the management of invasive fungal infections. Drugs 67:269-298.
57. Takada, K., M. Arefayene, Z. Desta, C. H. Yarboro, D. T. Boumpas, J. E. Balow, D. A. Flockhart, and G. G. Illei. 2004. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum. 50:2202-2210.
58. Tassaneeyakul, W., D. J. Birkett, M. E. Veronese, M. E. McManus, R. H. Tukey, L. C. Quattrochi, H. V. Gelboin, and J. O. Miners. 1993. Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J. Pharmacol. Exp. Ther. 265:401-407.
59. Theuretzbacher, U., F. Ihle, and H. Derendorf. 2006. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin. Pharmacokinet. 45:649-663.
60. Thummel, K. E., D. O'Shea, M. F. Paine, D. D. Shen, K. L. Kunze, J. D. Perkins, and G. R. Wilkinson. 1996. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther. 59:491-502.
61. Thummel, K. E., D. D. Shen, T. D. Podoll, K. L. Kunze, W. F. Trager, C. E. Bacchi, C. L. Marsh, J. P. McVicar, D. M. Barr, and J. D. Perkins. 1994. Use of midazolam as a human cytochrome P450 3A probe. II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J. Pharmacol. Exp. Ther. 271:557-566.
62. Thummel, K. E., D. D. Shen, T. D. Podoll, K. L. Kunze, W. F. Trager, P. S. Hartwell, V. A. Raisys, C. L. Marsh, J. P. McVicar, and D. M. Barr. 1994. Use of midazolam as a human cytochrome P450 3A probe. I. In vitro-in vivo correlations in liver transplant patients. J. Pharmacol. Exp. Ther. 271:549-556.
63. Totah, R. A., P. Sheffels, T. Roberts, D. Whittington, K. Thummel, and E. D. Kharasch. 2008. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 108:363-374.
64. Turpeinen, M., H. Raunio, and O. Pelkonen. 2006. The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico. Curr. Drug Metab. 7:705-714.
65. Wang, Y. H., D. R. Jones, and S. D. Hall. 2005. Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab. Dispos. 33:664-671.
66. Ward, B. A., J. C. Gorski, D. R. Jones, S. D. Hall, D. A. Flockhart, and Z. Desta. 2003. The cytochrome P4502B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther. 306:287-300.
67. Wilkinson, G. R. 2005. Drug metabolism and variability among patients in drug response. N. Engl. J. Med. 352:2211-2221.
68. Wrighton, S. A., J. C. Stevens, G. W. Becker, and M. Vandenbranden. 1993. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch. Biochem. Biophys. 306:240-245.
69. Zanger, U. M., K. Klein, T. Saussele, J. Blievernicht, H. Hofmann, and M. Schwab. 2007. Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics 8:743-759.
70. Zanger, U. M., M. Turpeinen, K. Klein, and M. Schwab. 2008. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal. Bioanal. Chem. 392:1093-1108.